Case report of lamivudine-resistant hepatitis B virus infection post liver transplantation from a hepatitis B core antibody donor

R. D. Yen, H. Bonatti, Julio C Mendez, J. Aranda-Michel, R. Satyanarayana, Rolland Dickson

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The use of allografts from donors with hepatitis B core antibody in liver transplantation (LT) is associated with the risk of de novo hepatitis B virus (HBV) infection. Prophylaxis using hepatitis B Immune globulin (HBIg) and lamivudine alone or in combination has been reported. Yet, there are no standardized regimens and long-term efficacy is not known. We report a case of a patient who underwent LT for alcoholic liver disease who received an allograft from a donor with Hepatitis B core antibody. The patient had no previous exposure to HBV, was vaccinated against HBV, and had demonstrated Hepatitis B surface antibody present in serum before and 6 months after transplantation. Prophylaxis with short-term HBIg (1 week) and indefinite lamivudine was given. De novo HBV infection developed more than 3 years after LT with a lamivudine-resistant polymerase mutant containing the rtM204I and rtl180L/M mutations. We reviewed the risk of de novo post-LT HBV infection in recipients of livers from hepatitis B core antibody positive donors. High risk were HBV naïve recipients, moderate risk recipients had isolated hepatitis B surface antibody (anti-HBs) or hepatitis B core antibody (anti-HBc), while low-risk recipients had both anti-HBs and anti-HBc. We reviewed prophylaxis protocols reported in the literature and made recommendations for management.

Original languageEnglish (US)
Pages (from-to)1077-1083
Number of pages7
JournalAmerican Journal of Transplantation
Volume6
Issue number5 I
DOIs
StatePublished - May 2006

Fingerprint

Hepatitis B Antibodies
Lamivudine
Virus Diseases
Hepatitis B virus
Liver Transplantation
Tissue Donors
Hepatitis B
Allografts
Immunoglobulins
Alcoholic Liver Diseases
Transplantation
Mutation
Liver
Serum

Keywords

  • Adefovir
  • Hepatitis B immune globulin
  • Prophylaxis
  • YMDD mutation

ASJC Scopus subject areas

  • Immunology

Cite this

Case report of lamivudine-resistant hepatitis B virus infection post liver transplantation from a hepatitis B core antibody donor. / Yen, R. D.; Bonatti, H.; Mendez, Julio C; Aranda-Michel, J.; Satyanarayana, R.; Dickson, Rolland.

In: American Journal of Transplantation, Vol. 6, No. 5 I, 05.2006, p. 1077-1083.

Research output: Contribution to journalArticle

@article{252fa3c470c64cbb897e1d9bb9b26268,
title = "Case report of lamivudine-resistant hepatitis B virus infection post liver transplantation from a hepatitis B core antibody donor",
abstract = "The use of allografts from donors with hepatitis B core antibody in liver transplantation (LT) is associated with the risk of de novo hepatitis B virus (HBV) infection. Prophylaxis using hepatitis B Immune globulin (HBIg) and lamivudine alone or in combination has been reported. Yet, there are no standardized regimens and long-term efficacy is not known. We report a case of a patient who underwent LT for alcoholic liver disease who received an allograft from a donor with Hepatitis B core antibody. The patient had no previous exposure to HBV, was vaccinated against HBV, and had demonstrated Hepatitis B surface antibody present in serum before and 6 months after transplantation. Prophylaxis with short-term HBIg (1 week) and indefinite lamivudine was given. De novo HBV infection developed more than 3 years after LT with a lamivudine-resistant polymerase mutant containing the rtM204I and rtl180L/M mutations. We reviewed the risk of de novo post-LT HBV infection in recipients of livers from hepatitis B core antibody positive donors. High risk were HBV na{\"i}ve recipients, moderate risk recipients had isolated hepatitis B surface antibody (anti-HBs) or hepatitis B core antibody (anti-HBc), while low-risk recipients had both anti-HBs and anti-HBc. We reviewed prophylaxis protocols reported in the literature and made recommendations for management.",
keywords = "Adefovir, Hepatitis B immune globulin, Prophylaxis, YMDD mutation",
author = "Yen, {R. D.} and H. Bonatti and Mendez, {Julio C} and J. Aranda-Michel and R. Satyanarayana and Rolland Dickson",
year = "2006",
month = "5",
doi = "10.1111/j.1600-6143.2006.01313.x",
language = "English (US)",
volume = "6",
pages = "1077--1083",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "5 I",

}

TY - JOUR

T1 - Case report of lamivudine-resistant hepatitis B virus infection post liver transplantation from a hepatitis B core antibody donor

AU - Yen, R. D.

AU - Bonatti, H.

AU - Mendez, Julio C

AU - Aranda-Michel, J.

AU - Satyanarayana, R.

AU - Dickson, Rolland

PY - 2006/5

Y1 - 2006/5

N2 - The use of allografts from donors with hepatitis B core antibody in liver transplantation (LT) is associated with the risk of de novo hepatitis B virus (HBV) infection. Prophylaxis using hepatitis B Immune globulin (HBIg) and lamivudine alone or in combination has been reported. Yet, there are no standardized regimens and long-term efficacy is not known. We report a case of a patient who underwent LT for alcoholic liver disease who received an allograft from a donor with Hepatitis B core antibody. The patient had no previous exposure to HBV, was vaccinated against HBV, and had demonstrated Hepatitis B surface antibody present in serum before and 6 months after transplantation. Prophylaxis with short-term HBIg (1 week) and indefinite lamivudine was given. De novo HBV infection developed more than 3 years after LT with a lamivudine-resistant polymerase mutant containing the rtM204I and rtl180L/M mutations. We reviewed the risk of de novo post-LT HBV infection in recipients of livers from hepatitis B core antibody positive donors. High risk were HBV naïve recipients, moderate risk recipients had isolated hepatitis B surface antibody (anti-HBs) or hepatitis B core antibody (anti-HBc), while low-risk recipients had both anti-HBs and anti-HBc. We reviewed prophylaxis protocols reported in the literature and made recommendations for management.

AB - The use of allografts from donors with hepatitis B core antibody in liver transplantation (LT) is associated with the risk of de novo hepatitis B virus (HBV) infection. Prophylaxis using hepatitis B Immune globulin (HBIg) and lamivudine alone or in combination has been reported. Yet, there are no standardized regimens and long-term efficacy is not known. We report a case of a patient who underwent LT for alcoholic liver disease who received an allograft from a donor with Hepatitis B core antibody. The patient had no previous exposure to HBV, was vaccinated against HBV, and had demonstrated Hepatitis B surface antibody present in serum before and 6 months after transplantation. Prophylaxis with short-term HBIg (1 week) and indefinite lamivudine was given. De novo HBV infection developed more than 3 years after LT with a lamivudine-resistant polymerase mutant containing the rtM204I and rtl180L/M mutations. We reviewed the risk of de novo post-LT HBV infection in recipients of livers from hepatitis B core antibody positive donors. High risk were HBV naïve recipients, moderate risk recipients had isolated hepatitis B surface antibody (anti-HBs) or hepatitis B core antibody (anti-HBc), while low-risk recipients had both anti-HBs and anti-HBc. We reviewed prophylaxis protocols reported in the literature and made recommendations for management.

KW - Adefovir

KW - Hepatitis B immune globulin

KW - Prophylaxis

KW - YMDD mutation

UR - http://www.scopus.com/inward/record.url?scp=33745243283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745243283&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2006.01313.x

DO - 10.1111/j.1600-6143.2006.01313.x

M3 - Article

C2 - 16611347

AN - SCOPUS:33745243283

VL - 6

SP - 1077

EP - 1083

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 5 I

ER -